Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
Ampronix
ElsMed

Simplified Alzheimer’s Disease Diagnosis Using PET Imaging and More Effective Criteria

By Medimaging International staff writers
Posted on 24 Jul 2014
According to French investigators, over one-third of patients receive an incorrect diagnosis of Alzheimer’s disease (AD). To reduce the number of errors, the diagnostic criteria available must be the most reliable possible, especially at the very early stages of the disease. For the past 10 years, an international team of neurologists has been working towards this objective. The researchers recently introduced new diagnostic criteria, in particular, biomarkers. These are authentic signatures of the disease, and are present from the first symptoms (prodromal stage).

In the June 2014 issue of the Lancet Neurology journal, Dr. Bruno Dubois, from the National de la Santé et de la Recherche Médicale (Inserm; Paris, France) and Pierre and Marie Curie University (Paris, France) /AP-HP Joint Research Unit 975) and colleagues have developed a simplified diagnosis based on the most specific criteria of the disease, which should have a major impact in clinical practice.

AD is the most common (70%) form of dementia. The real challenge of a definitive diagnosis is to know how to differentiate this disease from other types of dementia, and establish the diagnosis as effectively and as early as possible.

In 2005, an international group of neurologists, coordinated by Inserm’s Dr. Bruno Dubois, came together to redefine the diagnostic criteria established in 1984. Up to then, it had been necessary to await the death of a patient in order to establish a diagnosis of AD with certainty by examining the lesions in his/her brain. And in the living, only a probability of disease could be inferred, and only at a late stage, based on a certain threshold of severity of dementia.

In 2007, the international team broke these hypotheses apart. The researchers introduced new diagnostic criteria, particularly biomarkers. These are authentic signatures of the disease, and are present from the initial symptoms (prodromal stage). The publication of these findings initiated a transformation. Researchers then observed that with these new criteria, “36% of their patients included in a therapeutic trial based on previous clinical criteria did not have Alzheimer’s disease,” reported Prof. Dubois. However, although this analysis involved only a subgroup of patients, the implications are serious. Patients did not receive the correct treatment and/or care. Moreover, flawed patient selection might have had an impact on the lack of efficacy observed for the new treatment.

Since 2007, many studies have been published. The international group decided to analyze this literature to make the diagnostic algorithm for AD simpler and more reliable. “We have reached the end of the road; we have arrived at the essence, something refined, resulting from an international consensus,” indicated Prof. Dubois. The diagnosis of Alzheimer’s disease will henceforth rely on “just a couple of clinical-biological criteria for all stages of the disease.”

Most of the time, the diagnosis of AD is based primarily on a suggestive clinical picture. It is subsequently confirmed or rejected using a biomarker. As regards the clinical picture, there are three scenarios: (1) typical cases (80%–85% of all cases): impairment of episodic long-term memory (known as amnestic syndrome of the hippocampal type and corresponding to difficulty remembering a list a words, even with clues, for example); (2) atypical cases (15%–20% of cases): atrophy of the posterior part of the cerebral cortex or logopenic aphasia (impairment of verbal memory where the patient inverts the syllables of a word when repeating it, for example), or frontal brain damage, which results in behavioral problems; (3) preclinical states: asymptomatic at-risk (patients without symptoms, but who are fortuitously discovered to have positive biomarkers during scientific studies), and presymptomatic (with a genetic mutation).

One of the following two biomarkers is required: (1) in the cerebrospinal fluid (obtained by lumbar puncture) to ascertain abnormal levels of brain proteins (reduced beta amyloid protein and increased tau protein); (2) and in the brain by positron emission tomography (PET) neuroimaging to determine the elevated retention of amyloid tracer.

This simpler and more effective algorithm is important, mainly for research (therapeutic trials, characterization of the disease, monitoring of patient cohorts), according to the investigators. Outside of research, the use of biomarkers, which is expensive and/or invasive, currently remains limited to young patients or difficult or complex cases in specialty centers.

Related Links:
National de la Santé et de la Recherche Médicale
Pierre and Marie Curie University




Channels

Radiography

view channel

Healthcare Costs Could Be Cut by More Appropriate Use of Cardiac Stress Imaging

In new research, investigators concluded that overuse of cardiac stress testing using advanced imaging technology has led to increasing healthcare costs in the United States and unnecessary radiation exposure to patients. Researchers from the New York University Langone Medical Center (NYU; New York, NY, USA), in... Read more

MRI

view channel
Image: MagLab’s 900 MHz magnet (Photo courtesy of FSU – Florida State University).

High Magnetic Field MRI Technology Provides Comprehensive Analysis of Strokes

A new, novel way to categorize the severity of a stroke, help in diagnosis, and assesse potential treatments has been demonstrated by US researchers. “Stroke affects millions of adults and children... Read more

Ultrasound

view channel
Image: Leading German anesthetists Drs. Wolf Armbruster, Rüdiger Eichholz, and Thomas Notheisen have collaborated to develop the Armbruster Eichholz Notheisen (AEN) training concept for ultrasound-guided regional anesthesia (Photo courtesy of Management and Krankenhaus).

Point-of-Care Ultrasound Training Program Established for Regional Anesthesiologists

Regional anesthesia specialists have developed an innovative ultrasound training program. Leading German anesthetists Drs. Wolf Armbruster, Rüdiger Eichholz, and Thomas Notheisen have collaborated to... Read more

General/Advanced Imaging

view channel
Image: A collaborative effort between EPFL, CNRS, ENS Lyon, CPE Lyon, and ETH Zürich has led to the development of a novel approach that can considerably improve the capabilities of medical imaging with safer procedures for the patient (Photo courtesy of EPFL - Ecole Polytechnique Fédérale de Lausanne).

Collaboration to Make Diagnostic Medical Imaging Less Hazardous Using Hyperpolarization Agents

A collaborative effort by scientists has led to the development of an innovative strategy that can considerably improve the capabilities of medical imaging with safer procedures for the patient.... Read more

Imaging IT

view channel

Tabbed Barcodes and Management System Software Designed to Help Apron Tracking to Improve Radiology Inventory Management

A web-based inventory management system has been designed to link each radiology apron with a distinct barcode ID. As a cloud-based, decision support system, staff can track, audit, and maintain aprons using data sorted by department, area, and garment type. Healthcare personnel can see details on individual inspections... Read more

Industry News

view channel

Global Partnership Provides Treatment Planning Support for Modulated Arc Radiotherapy

Varian Medical Systems (Palo Alto, CA, USA) Eclipse treatment planning software can now be used to plan modulated arc radiotherapy (mARC) treatments at sites using Siemens Healthcare (Erlangen, Germany) medical linear accelerators. Varian Medical Systems and Siemens Healthcare presented their range of solutions that... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.